Literature DB >> 14612135

Monoamine transporters and psychostimulant drugs.

Richard B Rothman1, Michael H Baumann.   

Abstract

Most psychostimulants interact with monoamine transport proteins. This paper reviews work our laboratory has conducted to investigate the interaction of psychostimulants with monoamine transporters in order to advance our understanding of how these drugs affect the brain. We review two topics: (1) characterization of multiple binding sites for cocaine-like drugs and (2) an examination of the mechanisms of action of amphetamine-type anorectic agents. We conclude that the brain contains high abundance nonclassical binding sites for cocaine-like drugs that have micromolar affinity for cocaine and that none of the clinically available amphetamine-type appetite suppressants are equipotent substrates for dopamine transporter (DAT) and serotonin transporter (SERT) proteins. Future medications discovery efforts should focus on identifying new compounds which possess the equipotent substrate activity at DAT and SERT, but which lack the adverse effects of stimulants developed decades ago.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612135     DOI: 10.1016/j.ejphar.2003.08.054

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  180 in total

1.  In vivo comparison of norepinephrine and dopamine release in rat brain by simultaneous measurements with fast-scan cyclic voltammetry.

Authors:  Jinwoo Park; Pavel Takmakov; R Mark Wightman
Journal:  J Neurochem       Date:  2011-10-20       Impact factor: 5.372

Review 2.  Novel pharmacotherapeutic treatments for cocaine addiction.

Authors:  Daryl Shorter; Thomas R Kosten
Journal:  BMC Med       Date:  2011-11-03       Impact factor: 8.775

3.  Discriminative stimulus effects of NMDA, AMPA, and mGluR5 glutamate receptor ligands in methamphetamine-trained rats.

Authors:  Thomas E Wooters; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat.

Authors:  Michael H Baumann; Zakia Williams; Dorota Zolkowska; Richard B Rothman
Journal:  Drug Alcohol Depend       Date:  2010-11-10       Impact factor: 4.492

Review 5.  Synaptic optical imaging platforms: Examining pharmacological modulation of neurotransmitter release at discrete synapses.

Authors:  Paolomi Merchant; David Sulzer; Dalibor Sames
Journal:  Neuropharmacology       Date:  2015-03-30       Impact factor: 5.250

6.  Effects of monoaminergic drugs on training-induced motor cortex plasticity in older adults.

Authors:  Trisha M Kesar; Samir R Belagaje; Paola Pergami; Marc W Haut; Gerald Hobbs; Cathrin M Buetefisch
Journal:  Brain Res       Date:  2017-06-17       Impact factor: 3.252

Review 7.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

8.  Development of serotonin transporter reuptake inhibition assays using JAR cells.

Authors:  Ann M Decker; Bruce E Blough
Journal:  J Pharmacol Toxicol Methods       Date:  2018-03-16       Impact factor: 1.950

9.  Effects of methylphenidate on the aggressive behavior, serotonin and dopamine levels, and dopamine-related gene transcription in brain of male Nile tilapia (Oreochromis niloticus).

Authors:  Isabela Gertrudes Batalhão; Daína Lima; Ana Paula Montedor Russi; Camila Nomura Pereira Boscolo; Danilo Grunig Humberto Silva; Thiago Scremin Boscolo Pereira; Afonso Celso Dias Bainy; Eduardo Alves de Almeida
Journal:  Fish Physiol Biochem       Date:  2019-05-03       Impact factor: 2.794

Review 10.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.